Halozyme Therapeutics HALO Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's total current assets?
- Halozyme Therapeutics (HALO) reported total current assets of $1B in Q1 2026.
- How has Halozyme Therapeutics's total current assets changed year-over-year?
- Halozyme Therapeutics's total current assets decreased by 20.5% year-over-year, from $1.26B to $1B.
- What is the long-term trend for Halozyme Therapeutics's total current assets?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's total current assets has grown at a 8.3% compound annual growth rate (CAGR), from $554.76M to $825.21M.
- What does total current assets mean?
- The sum of all assets that the company expects to turn into cash within one year.
- How do you interpret total current assets?
- A higher total relative to current liabilities indicates a stronger ability to cover short-term obligations.
- How does total current assets compare across companies?
- Essential for calculating the current ratio, which is a standard benchmark for short-term solvency across all sectors.